Ilja Kubisch
Overview
Explore the profile of Ilja Kubisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kubisch I, Wohmann N, Wissniowski T, Stauch T, Oettel L, Diehl-Wiesenecker E, et al.
J Clin Med
. 2024 Nov;
13(22).
PMID: 39597922
: Acute intermittent porphyria (AIP) is a metabolic disease characterised by neurovisceral crises with episodes of acute abdominal pain alongside life-altering, and often hidden, chronic symptoms. The elimination of precipitating...
2.
Gerischer L, Mainert M, Wohmann N, Kubisch I, Stolzel U, Stauch T, et al.
Healthcare (Basel)
. 2024 Jan;
12(1).
PMID: 38201016
Porphyrias, as most rare diseases, are characterized by complexity and scarcity of knowledge. A national registry in one of the largest European populations that prospectively collects longitudinal clinical and laboratory...
3.
Ben Khaled N, Mortl B, Beier D, Reiter F, Pawlowska-Phelan D, Teufel A, et al.
Eur J Cancer
. 2023 Dec;
198:113499.
PMID: 38160177
No abstract available.
4.
Ben Khaled N, Mortl B, Beier D, Reiter F, Pawlowska-Phelan D, Teufel A, et al.
Eur J Cancer
. 2023 Sep;
192:113248.
PMID: 37672814
Background And Aims: The treatment of hepatocellular carcinoma (HCC) is undergoing a historic transformation with the approval of several new systemic therapies in the last few years. This study aimed...
5.
Diehl-Wiesenecker E, Blaschke S, Wohmann N, Kubisch I, Stauch T, Mainert M, et al.
Orphanet J Rare Dis
. 2023 Jun;
18(1):146.
PMID: 37308920
Background: Acute porphyrias (APs) are a group of rare metabolic diseases related to a disturbed heme biosynthesis. Symptoms may first occur as life threatening attacks, comprising abdominal pain and/or variable...
6.
Wang B, Ventura P, Takase K, Thapar M, Cassiman D, Kubisch I, et al.
Orphanet J Rare Dis
. 2022 Aug;
17(1):327.
PMID: 36028858
Background: Acute hepatic porphyria (AHP) is a family of four rare genetic diseases, each involving deficiency in a hepatic heme biosynthetic enzyme. Resultant overproduction of the neurotoxic intermediates δ-aminolevulinic acid...
7.
Ben Khaled N, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rossler D, et al.
Future Oncol
. 2022 Jan;
18(12):1423-1435.
PMID: 35081747
The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab is the first approved immunotherapeutic regimen for first-line therapy in patients with unresectable hepatocellular carcinoma (HCC), currently approved in...
8.
Brunk T, Schmidt A, Hochberger J, Wedi E, Meier B, Braun G, et al.
Minim Invasive Ther Allied Technol
. 2021 Aug;
31(5):704-711.
PMID: 34342252
Introduction: Risk stratification in upper gastrointestinal bleeding (UGIB) currently relies on clinical parameters and risk scores. HemoPill acute (Ovesco Endoscopy, Tuebingen, Germany) is a pill-shaped, orally administered sensor capsule for...
9.
Stolzel U, Stauch T, Kubisch I
Internist (Berl)
. 2021 Jun;
62(9):937-951.
PMID: 34185109
Porphyrias are caused by enzyme defects along the heme biosynthetic pathway. The first line diagnosis of porphyria is based on specific biochemical patterns of elevated porphyrins and porphyrin precursors in...
10.
Kubisch I, de Albuquerque A, Schuppan D, Kaul S, Schaich M, Stolzel U
Oncology
. 2015 Aug;
89(5):294-303.
PMID: 26315108
Objective: We aimed to assess the prognostic value of circulating tumor cells (CTC) in patients with advanced gastric and gastroesophageal adenocarcinomas. Methods: The presence of CTC was evaluated in 62...